Douglas Kerr - 16 Jun 2026 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: Chief Medical Officer
Issuer ticker: DYN
Reported as of: 16 Jun 2026
Net transaction value: -$16,259
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:08:45 UTC
Prior SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ron Caponigro, Attorney-in-Fact

Key filing fact

Douglas Kerr filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 17 Jun 2026.

Key facts

This page summarizes Douglas Kerr's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 16:08.

Change

Previous filing in this sequence was filed on 14 May 2026.
Current net transaction value: -$16,259.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814189 Primary reporting owner

Kerr Douglas

Relationship: Chief Medical Officer
Address: C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM
Signature: /s/ Ron Caponigro, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DYN transaction

Common Stock

Sale

Transaction value: $16,259
Shares: -887
Change %: -0.52%
Price: $18.33
Shares after: 169,155
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

Footnote F3

Includes 145,313 unvested RSUs.